

European Health Technology Institute on Socio-Economic Research

Background,
Research Topics,
Concept, Framework

Prof. Dr. med. Reinhard Busse MPH

Dept. Health Care Management, Berlin University of Technology &
European Observatory on Health Systems and Policies


Background

Medical technology industry in terms of employment and turnover similar to pharmaceuticals but less “visible” in policy and academia

- > scarcity of European data on cost-benefit (“value”) of medical technologies
- > might lead to application of evaluation and regulatory instruments derived from pharmaceuticals (e.g. Health Technology Assessment)


Currently ...

policy objectives



way of medical devices into and through the health care system

Soon?




Addressing gaps and challenges – Research on Medical Technology

- Aims and objectives
 - Conduct high level research on the economic and health implications of medical technologies, in particular, medical devices
 - Bridge the gap between medical technology industry, academia and health policy
 - Provide decision-makers with robust evidence on the social & economic value of medical technology
 - Contribute to the debate on access, availability, diffusion and optimal use of medical technologies in Europe

Addressing gaps and challenges – The (initial) research agenda

- Bringing health technologies onto academic (-> *publications*) and policy agendas
- Understanding market access, coverage, financing, utilisation and actual/ potential benefit of selected technologies
- Comparing regulatory policies across countries and technologies in respect to current (and future) economic, health and social policy objectives and overall „value for society“
- Identifying „good“ and „bad“ regulatory policies in order to help shaping future policy



Note: underlined technologies are part of the first part of the project

1 General structure of Health Basket (whole health care system of one country)

- 1.1 Level of regulation
- 1.2 Numbers and types of regulatory regimes
- 1.3 Role of central government

2 Definitions of entitlements and benefits for sectors relevant for medical devices (HC 1.1 (Inpatient), HC 1.3 (Outpatient), HC 5.2 (goods in outpatient care))

- 2.1 Responsible actors
- 2.2 Definition of benefits
- 2.3 Classification of benefits
- 2.4 Involved actors and decision criteria

3 Actual coverage status of selected technologies

(I: incontinence pads, II: knee endoprotheses, IDCs)

4 Financing aspects concerning “price”



(goods manufacturer / service provider -> manufacturer)

5 Financing aspects concerning reimbursement

(including cost-sharing): third-party payer/ patient -> service provider/ goods distributor)

6 Access to technology

- 6.1 patient getting technology from ...
- 6.2 decision makers



Note: the numbers I, II, IIIa and IIIb refer to the technology categories in figure 1

Bridging research objectives, issues, technologies, countries ...

	Technology A	Technology B	Technology ..	Technology Z	“Medical technologies”
Technology Assessment & Coverage Decisions					
Prioritisation: who decides what should be assessed?	Country I, II, III ...				
HTA process: who? which criteria (eff., cost-eff. ...)?	Country I, II, III	Country I, II, III	Country I, II, III	Country I, II, III	
Decision: by whom? based on what criteria?	Country I, II, III ...				
Actual decision	Country I, II, III	Country I, II, III	Country I, II, III	Country I, II, III	
Financing					
Budget-setting & allocation to regions ..., medical technologies	Country I, II, III ...				
Reimbursement of medical technologies in hospital	Country I, II, III	Country I, II, III	Country I, II, III	Country I, II, III	
Reimbursement of medical technologies in outpatient care	Country I, II, III	Country I, II, III	Country I, II, III	Country I, II, III	
Value to society					
Epidemiology: how many patients?	Country I, II, III	Country I, II, III	Country I, II, III	Country I, II, III	
Medical benefit/ patient	Country I, II, III	Country I, II, III	Country I, II, III	Country I, II, III	
Cost-effectiveness/ patient	Country I, II, III	Country I, II, III	Country I, II, III	Country I, II, III	
Other benefits ...	Country I, II, III	Country I, II, III	Country I, II, III	Country I, II, III	
Uptake (linkage to financing?)/ (in)appropriate utilisation	Country I, II, III	Country I, II, III	Country I, II, III	Country I, II, III	
Overall benefit	Country I, II, III	Country I, II, III	Country I, II, III	Country I, II, III	Final objective